AGTC Presents New Data on its AAV-Based Gene Therapies for the Treatment of Achromatopsia and X-Linked …NasdaqWASHINGTON, May 11, 2017 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting huma… Continue reading
Global Cancer Immunotherapy Research Report 2017GlobeNewswire (press release)This new report includes an updated discussion of approved and clinical stage agents in immuno-oncology, including recently-approved agents. It also addresses the means by whi… Continue reading
Global Cancer Immunotherapy Research Report 2017GlobeNewswire (press release)This new report includes an updated discussion of approved and clinical stage agents in immuno-oncology, including recently-approved agents. It also addresses the means by whi… Continue reading
FierceBiotechPfizer doubles down on gene therapy pipeline with $70M Sangamo buy-inFierceBiotechAfter deals and acquisitions with Spark Therapeutics and Bamboo, Pfizer is once again looking to bolster its rare and gene therapy pipeline as it outlines a … Continue reading
Researchers use CRISPR to develop a Ewing sarcoma stem cell modelMedical XpressA team from the Spanish National Cancer Research Centre (CNIO) has optimized a system capable of generating a cellular model of Ewing sarcoma. The technique, based on … Continue reading
Cancer NetworkFlu Vaccine in Lung Cancer Patients Could Increase Immunotherapy ToxicitiesCancer NetworkSeasonal influenza vaccination resulted in increased risk of immune-related adverse events (AEs) in lung cancer patients treated with PD-1/PD-L1 chec… Continue reading
|
Oxford Genetics Strikes Licensing Agreement for CRISPR Gene Editing Tech
R & D Magazine Licensing the CRISPR gene editing technology from ERS Genomics is another step on our journey to establishing the most efficient and integrated service portfolio in this sector,” commented Dr. Paul Brooks, Ph.D., CCO, Oxford Genetics. “We are excited … |
Labiotech.eu (blog) |
Video: Meet the CEO developing Gene Therapy without Viral Vectors
Labiotech.eu (blog) Eyevensys has found a way to deliver gene therapy without viral vectors. Clara caught up with the company’s CEO Raffy Kazandjian at BioTrinity to hear more. Eyevensys is based in Paris and has set itself the mission of enhancing current treatment … |